The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1489
Elbasvir/Grazoprevir (Zepatier) for Hepatitis C
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Zepatier (Merck), a fixed-dose combination of two direct-acting antiviral agents — elbasvir, an NS5A inhibitor, and grazoprevir, an NS3/4A protease inhibitor — for oral treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection.

HCV GENOTYPES — Genotype 1 is responsible for 70-80% of HCV infections in the US. Genotype 4 is uncommon in the US and Canada; it is the most prevalent strain of HCV in Central sub-Saharan Africa, North Africa, and the Middle East.1

FIXED-DOSE COMBINATIONS — Zepatier is the third all-oral, interferon-free, fixed-dose combination to be approved for treatment of infections with HCV genotypes 1 and 4. The combination of ledipasvir/sofosbuvir (Harvoni) was approved for HCV genotype 1 infection in 20142 and for genotypes 4, 5, and 6 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Elbasvir Grazoprevir (Zepatier) for Hepatitis C
Article code: 1489a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian